2014

1. Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: A multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group

   Leukemia and Lymphoma, Vol. 55, Núm. 1, pp. 51-55